Method could hold the key to better treatment of epilepsy and schizophrenia Researchers are exploring new ways to ‘listen’ to and record electrical signals emitted from brain cells Findings could be used to help treat conditions like epilepsy and schizophrenia Project will use newly developed nanomaterials to keep removed samples of brain healthy for longer…
Category: Epilepsy
Cenobamate (ONTOZRY®) now available in The Netherlands
Angelini Pharma, an international pharmaceutical company part of the privately held Italian Angelini Group announced on 4 April 2022 that ONTOZRY® (cenobamate) is now available in the Netherlands for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adults patients who have not been adequately controlled despite an history of treatment with…
Bial and Medis partnership
13 July 2021: BIAL and Medis, d.o.o. have entered into an exclusive partnership on two of BIAL’s proprietary drugs: Zebinix® (eslicarbazepine acetate) and Ongentys® (opicapone). The established partnership comprises an exclusive distribution agreement for Zebinix® (eslicarbazepine acetate) in the Czech Republic and Slovakia and an exclusive distribution agreement for Ongentys® (opicapone) in 12 CEE countries…
Funding boost for AI-based epilepsy monitoring
University spinout company Neuronostics has received funding to develop its BioEP platform, an AI-based system for faster, more accurate diagnosis of epilepsy and to monitor response to treatment with anti-epileptic drugs (AEDs). BioEP works by creating mathematical models of the brain using short segments of electroencephalogram (EEG) recordings. Computer simulations rapidly reveal the ease with…
